On October 26, media reported that according to the studies of "Pharmaceutical Quality System Research Project" issued by Pharmaceutical Development and Research Commission under China Association of Enterprises with Foreign Investment（CAEFI）, U.S. pharmaceutical companies take up to 64% in the Chinese mainland market. The accumulated market share of top ten Chinese pharmaceutical companies is less than 5%. The report also shows that China’s pharmaceutical industry is dominated by generic drugs and innovative drugs occupy less than 30% of market share.

　　Experts pointed out that the main reason for the low competitiveness of China's pharmaceutical industry is the lack of R&D input and innovative drugs, so it is difficult to lead the pharmaceutical market.

　　In developed countries, the value of patent medicine accounts for more than a half in the whole pharmaceutical market. However, according to the statistics from Chinese Health Economics Institute, over 97% of the China-made drugs are generic drugs and foreign pharmaceutical companies and joint ventures occupy the market of patent medicine and original drugs. The lack of innovative drugs with independent intellectual property becomes a major weakness of Chinese pharmaceutical companies.

　　                                                                  By IP Channel of People's Daily Online